Jade Biosciences (JBIO) vs Rigel Pharmaceuticals (RIGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Rigel Pharmaceuticals (RIGL) has outperformed Jade Biosciences (JBIO) over the past year, gaining 62.7% versus a gain of 52.3%. Over five years, RIGL leads with a +42.0% price change compared with -97.2% for JBIO. Rigel Pharmaceuticals is the larger company by market cap ($896.4 million vs $875.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JBIO | RIGL |
|---|---|---|
| Share price | $13.77 | $47.99 |
| Market cap | $875.74M | $896.45M |
| 1-day change | +2.68% | +4.08% |
| YTD return | -10.76% | +12.05% |
| 1-year return | +52.32% | +62.68% |
| 5-year return | -97.22% | +41.98% |
| P/E ratio (TTM) | — | 2.84 |
| Forward P/E | — | 9.72 |
| EPS (TTM) | $-1.92 | $16.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.00 | $52.24 |
| 52-week low | $8.36 | $24.95 |
| Distance from 52-week high | -50.82% | -8.14% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +264.05% | +31.28% |
| Average volume | 887.66K | 291.58K |
| Shares outstanding | 63.60M | 18.68M |
| Employees | 55 | 172 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RIGL has outperformed JBIO by 10.4 percentage points over the past year.
About Jade Biosciences
JBIO stock →Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases.
Healthcare · Biotechnology · 55 employees
About Rigel Pharmaceuticals
RIGL stock →Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.
Healthcare · Biotechnology · 172 employees
JBIO vs RIGL FAQ
Which is bigger, Jade Biosciences or Rigel Pharmaceuticals?
Rigel Pharmaceuticals (RIGL) is larger, with a market capitalization of $896.45M compared with $875.74M for Jade Biosciences (JBIO).
Which stock has performed better over the past year, JBIO or RIGL?
RIGL returned +62.68% over the past 12 months, compared with +52.32% for JBIO (price return, excluding dividends). Past performance does not predict future results.
Are Jade Biosciences and Rigel Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.